乳腺癌化疗前后表皮生长因子受体表达的变化及其意义  

Expression of epidermal growth factor receptor in breast carcinoma before and after chemotherapy and its significance

作　　者：包芸[1] 王文娟[1] 唐峰[1] 李琼[1] 陈忠清[1] 许祖德[1] 

机构地区：[1]复旦大学附属华山医院病理科,上海200040

出　　处：《复旦学报（医学版）》2011年第3期198-203,共6页Fudan University Journal of Medical Sciences

基　　金：国家自然科学基金项目(30872971)

摘　　要：目的本研究主要观察乳腺癌患者的表皮生长因子受体(epidermal growth factor receptor,EGFR)、C-erbB-2、CD147及Ki67在P-gp底物化疗药短期化疗前后蛋白表达的变化,并探讨其临床意义。方法采用免疫组织化学方法,分别对40例乳腺癌组织标本进行短期化疗前后EGFR、C-erbB-2、CD147及Ki67的表达进行评估。结果化疗后,EGFR表达比化疗前明显增加(80.0%vs.42.5%,P<0.01),C-erbB-2、CD147和Ki67表达则明显下降,但只有Ki67有统计学意义(32.5%vs.85.0%,P<0.01)。EGFR过表达及缺乏C-erbB-2表达(无论化疗前后)的患者更容易有淋巴结转移。EGFR、C-erbB-2和Ki67表达之间及与临床病理特点之间未见明显相关性。结论短期化疗既可杀伤肿瘤细胞,使Ki67增生减弱,也可诱导EGFR表达增强,但并不引起CD147等下游因子的表达,即不足以引起肿瘤细胞的转移。Objective To assess the expression of epidermal growth factor receptor（EGFR）,HER2/c-neu（ErbB-2;C-erbB-2） and other tumor metastasis and proliferation related molecules（CD 147;Ki67） before and after chemotherapy with P-glycoprotein（P-gp） substrates in breast carcinoma,so as to explore their clinical significance. Methods EGFR,C-erbB-2,CD147 and Ki67 expression were assessed in 40 tissue samples from breast carcinoma before and after short-term chemotherapy with P-gp substrates by immunohistochemistry. Results The expression of EGFR was increased after chemotherapy with P-gp substrates（80.0% vs.42.5%,P〈0.01）.Meanwhile,the expression of C-erbB-2,CD147 and Ki67 were decreased,but only Ki67 showed significant change（32.5% vs.85.0%,P〈0.01）.We also found that patients with EGFR over-expression and lack of C-erbB-2 expression（either before or after chemotherapy） were likely to have lymph node metastasis.No association was found among EGFR,C-erbB-2 and Ki67 expression,or among clinicopathologic features.Conclusions Short-term chemotherapy can kill tumor cells and decrease Ki67 proliferation,meanwhile,it can increase EGFR expression,but doesn’t result in expression of CD147 and other downstream factors that cause the transfer of tumor cells.

关 键 词：乳腺癌 表皮生长因子受体 C-ERBB-2 化疗 免疫组织化学 

分 类 号：R375.1[医药卫生—病原生物学]